A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus

Phase 2

Terminated

• Conditions: Type 2 Diabetes Mellitus; Diabetes Mellitus, Type 2

• Registration Number: NCT00437164
• Lead Sponsor: GlaxoSmithKline

Brief Summary

Many drugs used for the treatment of Type 2 Diabetes Mellitus cause the body to retain water. This study will assess whether or not GW677954 causes the body to retain fluid.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-09
• Primary Completion: 2006-11
• Study Completion: 2006-11
• Study First Submitted: 2007-02-16
• Study First Submitted QC: 2007-02-16
• Study First Posted: 2007-02-19
• Status Verified: 2011-05
• Last Update Submitted: 2012-05-31
• Last Update Posted: 2012-06-04

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
changes in fluid related parameters as measured by hematocrit and hemoglobin levels and body weight	up to 24 weeks

Secondary Outcome Measures

Name	Time	Method
safety/tolerability, as measured by adverse events, clinical laboratory, edema & glycemic measures, ophthalmic assessments; & changes in weight, waist & hip circumference	up to 24 weeks

Trial Locations

Locations (1)

GSK Investigational Site; 🇺🇸 Beverly Hills, California, United States